Breaking News

TCR² Therapeutics, ElevateBio Expand TC-210 Mfg. Capacity

Strategic partnership will leverage technical capabilities at ElevateBio for the production of TC-210 to support Phase II clinical trial.

By: Contract Pharma

Contract Pharma Staff

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing a novel T cell therapies for cancer, has established a manufacturing partnership with ElevateBio, LLC, to leverage technical capabilities at ElevateBio BaseCamp, a cell and gene therapy manufacturing facility in Waltham, MA. The strategic partnership will focus on the production of TC-210, TCR2’s TRuC-T cell targeting advanced mesothelin-expressing cancer, to support the anticipated Phase II clinical trial. Elevate Base...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters